UPPSALA, February 8, 2012 -- Isconova AB announces that its partner, VetBioChem, has launched two new dog and cat rabies vaccines on the Russian market. Both vaccines contain Isconova’s Matrix-MTMVet adjuvant, and
Isconova will receive production revenues and royalties on sales.
Since 2010 Isconova and VetBioChem, a leading Russian animal health company, have collaborated
on the development of rabies vaccines for dogs and cats, and these vaccines, Rabix and Rabifel, are
the first marketed veterinary vaccines using Isconova’s adjuvant Matrix-M™Vet. The agreement with
VetBioChem includes revenues for Isconova for the supply of Matrix-M™Vet as well as royalties
based on future sales of the rabies vaccines.
Russell Greig, acting CEO of Isconova, commented;
“We are very pleased that Rabix and Rabifel have been launched in Russia where rabies is a serious
problem for both animals and humans. The launch of these Matrix-M™ based vaccines is further
validation of our adjuvant technology platform and marks another step towards launching additional
vaccines based on Isconova’s enabling technology in new markets.”
For more information, please contact:
Gerd Rundström, COO, Isconova AB
Tel +46 18 16 17 06, e-mail: email@example.com
Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the
company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s
nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2006. In the human market
a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s
partners include Crucell/J&J, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered
in Uppsala, Sweden.
Isconova AB is listed on NASDAQ OMX First North (ticker: ISCO). Pareto Öhman AB is the Company’s Certified Adviser.
VetBioChem (NPO Narvac) is a leading animal health company in Russia. VetBioChem produces vaccines, diagnostics and
therapeutics for cattle, pigs and companion animals. www.vetbiochem.com
Matrix-M™ is Isconova’s patented adjuvant for use in vaccines for humans and some animals, antibody production and
immunological research. Matrix-M™Vet is used in animal vaccines.
Adjuvants are substances that improve the efficacy and duration of protection of vaccines.